Journal
ENT-EAR NOSE & THROAT JOURNAL
Volume 100, Issue 1, Pages 44-47Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/0145561320964653
Keywords
biologics; dupilumab; mepolizumab; omalizumab; benralizumab; chronic rhinosinusitis with nasal polyps (CRSwNP); nasal polyps
Categories
Funding
- National Institute of Health [T32AI083216]
- Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine
- Ernest Bazley Foundation
Ask authors/readers for more resources
Biologic therapy, represented by dupilumab, is a new treatment option for chronic rhinosinusitis with nasal polyps. Other biologics like mepolizumab and omalizumab may also gain approval based on promising trial results, but the role of biologics in treatment requires consideration of multiple factors.
Biologic therapy is a new treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, the only biologic with Food and Drug Administration-approval status for CRSwNP is dupilumab. Several other biologics are likely to be approved for CRSwNP, including mepolizumab and omalizumab, based on their promising phase 3 trial results. The role of biologics in the treatment paradigm requires consideration of multiple factors that have yet to be clearly established. This includes identifying patients most appropriate for biologic therapy while considering long-term safety and cost-effectiveness in the context of patient preferences and goals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available